Table 2.
Predictors of leukemic transformation in the first 5 years of diagnosis (Logistic regression analysis) | Risk factors for leukemia-free survival (Cox analysis) | |||
---|---|---|---|---|
Variables | Univariate analysis P value (OR, 95% CI) | Multivariable analysis P value (OR, 95% CI) | Univariate analysis P value (HR, 95% CI) | Multivariable analysis P value (HR, 95% CI) |
Age in years | <0.001 | 0.01 (1.02, 1–1.03) | ||
Age > 70 years | 0.003 (2.1, 1.3–3.3) | <0.001 (13.3, 3.5–51.2) | 0.4 (1.2, 0.8–1.7) | 0.03 (2.1, 1.1–3.8) |
Gender (Male) | <0.001 (2.8, 1.7–4.6) | 0.01 (6.9, 1.6–30.2) | 0.002 (1.7, 1.2–2.5) | |
Sex and severity adjusted anemia | ||||
“N” evaluable = 1298 | ||||
Moderate/Severe anemia | < 0.001 (3.1, 2.0–4.9) | 0.02 (3.6, 1.2–10.7) | < 0.001 (1.8, 1.3–2.6) | 0.02 (1.9, 1.1–3.3) |
No/Mild anemia | Reference | Reference | ||
Platelets, ×109/l “N” evaluable = 1299 | <0.001 | 0.05 (0.2, 0.04–1.03) | ||
Platelets<100 × 109/l “N” evaluable = 1299 | <0.001 (3.6, 2.1–6.1) | 0.001 (1.9, 1.3–2.8) | ||
Leukocytes, ×109/l “N” evaluable = 1298 | <0.001 | <0.001 (17, 3.9–51.4) | ||
Leukocytes > 25 × 109/l “N” evaluable = 1298 | 0.002 (3.4, 1.8–6.3) | 0.01 (1.8, 1.1–2.8) | ||
Circulating blasts % “N” evaluable = 1283 | <0.001 | <0.001 (18.5, 7.3–41.6) | ||
Circulating blasts ≥ 3% “N” evaluable = 1283 | <0.001 (3.6, 2.2–6.1) | 0.009 (5.5, 1.5–19.6) | <0.001 (2.6, 1.7–3.7) | 0.001 (3.3, 1.6–6.2) |
Palpable splenomegaly “N” evaluable = 1260 | 0.4 (0.8, 0.5–1.3) | 0.3 (0.8, 0.6–1.2) | ||
Bone marrow fibrosis grade (2 or above) “N” evaluable = 793 | 0.5 (0.8, 0.4–1.5) | 0.6 (0.9, 0.6–1.5) | ||
Constitutional symptoms “N” evaluable = 1302 | <0.001 (2,5, 1.5–3.9) | 0.04 (3.1, 1.0–9.2) | 0.009 (1.6, 1.1–2.3) | |
Any thrombosis at or prior to diagnosis “N” evaluable = 1299 | 0.3 (0.7, 0.3–1.4) | 0.08 (0.6, 0.4–1.1) | ||
Venous thrombosis at or prior to diagnosis “N” evaluable = 1298 | 0.2 (0.5, 0.1–1.4) | 0.04 (0.4, 0.2–1) | ||
Arterial thrombosis at or prior to diagnosis “N” evaluable = 1299 | 0.8 (1.1, 0.5–2.2) | 0.7 (0.9, 0.5–1.6) | ||
Presence of very high-risk (VHR) karyotype | <0.001 (10.9, 3.7–32.3) | 0.005 (57.6, 3.3–994) | <0.001 (3.6, 1.9–6.3) | |
Karyotype | ||||
“N” evaluable = 1218 | ||||
VHR | <0.001 (12, 4–35.7) | <0.001 (3.9, 2–7) | ||
Unfavorable | 0.08 (1.6, 0.9–2.9) | 0.05 (1.6, 1–2.9) | ||
Favorable | Reference | Reference | ||
Driver mutational status | ||||
“N” evaluable = 897 | ||||
JAK2 | 0.7 (0.9, 0.5–1.5) | 0.2 (0.7, 0.5–1.1) | ||
CALR | 0.2 (0.6, 0.3–1.3) | 0.9 (0.9, 0.6–1.6) | ||
MPL | 0.5 (1.3, 0.4–3.7) | 0.5 (1.3, 0.5–2.6) | ||
Triple-negative | 0.05 (2.2, 0.9–4.7) | 0.06 (1.9, 0.9–3.3) | ||
CALR type 1/like absent | 0.045 (2.2, 1.0–4.9) | 0.7 (1.1, 0.7–1.8) | ||
Mutations | ||||
ASXL1 mutated “N” evaluable = 596 | <0.001 (3.8, 2–7.2) | <0.001 (15.1, 4.0–56.7) | <0.001 (2.2, 1.4–3.5) | 0.01 (2.0, 1.2–3.3) |
SRSF2 mutated “N” evaluable = 597 | <0.001 (8.04, 3.7–17.2) | 0.002 (8.5, 2.2–32.2) | <0.001 (3.5, 2.1–5.7) | 0.001 (3.0, 1.6–5.3) |
IDH1 mutated “N” evaluable = 479 | 0.005 (23.5, 2.5–217) | 0.002 (78.4, 5.3–1153) | 0.006 (6.2, 1.9–15.4) | 0.03 (4.3, 1.2–11.7) |
IDH2 mutated “N” evaluable = 479 | 0.002 (9.9, 2.3–43.7) | 0.01 (3.1, 1.1–7.1) | ||
EZH2 mutated “N” evaluable = 452 | 0.4 (1.9, 0.4–9.7) | 0.7 (1.3, 0.2–4.2) | ||
U2AF1 mutated “N” evaluable = 579 | 0.09 (2, 0.9–4.6) | 0.3 (1.4, 0.7–2.7) | ||
U2AF1 Q157 mutated “N” evaluable = 579 | 0.3 (1.8, 0.6–5.9) | 0.5 (1.4, 0.5–3) |
Abbreviation: OR odds ratio, HR hazard ratio, CI confidence interval
Bold values indicates significance indicator